6706
G. Zheng et al. / Bioorg. Med. Chem. Lett. 17 (2007) 6701–6706
Marks, M. J.; Quik, M.; Taylor, P. W.; Wonnacott, S.
Pharmacol. Rev. 1999, 51, 397.
5. Cachelin, A. B.; Rust, G. Pflugers Arch. Eur. J. Physiol.
1995, 429, 449.
26. Grady, S. R.; Murphy, K. L.; Cao, J.; Marks, J. M.;
McIntosh, J. M.; Collins, A. C. J. Pharmacol. Exp. Ther.
2002, 301, 651.
27. Kaiser, S. A.; Soliakov, L.; Harvey, S. C.; Luetje, C. W.;
Wonnacott, S. J. Neurochem. 1998, 70, 1069.
28. Kaiser, S.; Wonnacott, S. Mol. Pharmacol. 2000, 58, 312.
29. Kulak, J. M.; Nguyen, T. A.; Olivera, B. M.; McIntosh, J.
M. J. Neurosci. 1997, 17, 5263.
30. Crooks, P. A.; Ayers, J. T.; Xu, R.; Sumithran, S. P.;
Grinevich, V. P.; Deaciuc, A. G.; Wilkins, L. H.; Allen, D.
D.; Dwoskin, L. P. Bioorg. Med. Chem. Lett. 2004, 14,
1869.
6. Harvey, S. C.; Luetje, C. W. J. Neurosci. 1996, 16, 3798.
7. Clarke, P. B.; Pert, A. Brain Res. 1985, 348, 355.
8. Corrigall, W. A.; Franklin, K. B. J.; Coen, K. M.; Clarke,
P. B. S. Psychopharmacology 1992, 107, 285.
9. McGehee, D. S.; Role, L. W. Annu. Rev. Physiol. 1995, 57,
521.
10. (a) Teng, L.; Crooks, P. A.; Buxton, S. T.; Dwoskin, L. P.
J. Pharmacol. Exp. Ther. 1997, 283, 778; (b) Teng, L.;
Crooks, P. A.; Sonsalla, P. K.; Dwoskin, L. P.
J. Pharmacol. Exp. Ther. 1997, 283, 1432.
11. Wonnacott, S. Trends Neurosci. 1997, 20, 92.
12. Laviolette, S. R.; van der Kooy, D. Mol. Psych. 2003, 8,
50.
31. Sonogashira, K.; Tohda, Y.; Hagihara, N. Tetrahedron
Lett. 1975, 16, 4467.
32. Nicolaou, K. C.; Zuccarello, G.; Riemer, C.; Estevez, V.
A.; Dai, W. M. J. Am. Chem. Soc. 1992, 114, 7360.
33. Dwoskin, L. P.; Joyce, B. M.; Zheng, G.; Neugebauer, N.
M.; Manda, V. K.; Lockmanc, P.; Papke, R. L.; Bardo,
M. T.; Crooks, P. A. Biochem. Pharmacol. 2007, 74, 1271.
34. Wilkins, L. H.; Grinevich, V. P.; Ayers, J. T.; Crooks, P. A.;
Dwoskin, L. P. J. Pharmacol. Exp. Ther. 2003, 304, 400.
35. Spectral data of compounds 3a, 3b, and 4b: for compound
3a, 1H NMR (300 MHz, CD3OD) d 9.01 (dd, J = 6.3,
0.9 Hz, 3H), 8.44 (dt, J = 7.8, 1.5 Hz, 3H), 7.92–8.07 (m,
6H), 7.41 (s, 3H), 4.81 (t, J = 6.0 Hz, 6H), 2.98 (s, 9H),
2.70 (t, J = 7.2 Hz, 6H), 2.29 (m, 6H) ppm; 13C NMR
(75 MHz, CD3OD) d 157.1, 146.8, 146.6, 134.9, 131.6,
127.1, 125.4, 90.1, 81.6, 58.4, 29.9, 20.7, 17.3 ppm; ESI-
13. Rahman, S.; Zhang, J.; Corrigall, W. A. Neurosci. Lett.
2003, 48, 61.
14. Crooks, P. A.; Ravard, A.; Wilkins, L. H.; Teng, L. H.;
Buxton, S. T.; Dwoskin, L. P. Drug Dev. Res. 1995, 36, 91.
15. Wilkins, L. H.; Haubner, A.; Ayers, J. T.; Crooks, P. A.;
Dwoskin, L. P. J. Pharmacol. Exp. Ther. 2002, 301, 1088.
16. Dwoskin, L. P.; Xu, R.; Ayers, J.; Crooks, P. A. Exp.
Opin. Ther. Patents 2000, 10, 1561.
17. Dwoskin, L. P.; Crooks, P. A. J. Pharmacol. Exp. Ther.
2001, 298, 395.
18. Dwoskin, L. P.; Sumithran, S. P.; Zhu, J.; Deaciuc, A. G.;
Ayers, J. T.; Crooks, P. A. Bioorg. Med. Chem. Lett. 2004,
14, 1863.
19. Zheng, F.; Bayram, E.; Sumithran, S. P.; Ayers, J. T.;
Zhan, C.; Schmitt, J. D.; Dwoskin, L. P.; Crooks, P. A.
Bioorg. Med. Chem. 2006, 14, 3017.
20. Rahman, S.; Neugebauer, N. M.; Zhang, Z.; Crooks, P.
A.; Dwoskin, L. P.; Bardo, M. T. Neuropharmacology
2007, 52, 755.
21. Neugebauer, N. M.; Zhang, Z.; Crooks, P. A.; Dwoskin,
L. P.; Bardo, M. T. Psychopharmacology 2006, 184, 426.
22. Ayers, J. T.; Dwoskin, L. P.; Deaciuc, A. G.; Grinevich, V.
P.; Zhu, J.; Crooks, P. A. Bioorg. Med. Chem. Lett. 2002,
12, 3067.
23. Cartier, G. E.; Yoshikami, D.; Gray, W. R.; Luo, S.;
Olivera, B. M.; McIntosh, J. M. J. Biol. Chem. 1996, 271,
7522.
MS:
m/z
710.0/711.9/713.9
[M]1+
(calcd
for
[C39H42N3Br2]1+ 710.18/712.18/714.18), 632.1 [M]2+ (calcd
for [C39H42N3Br]2+ 631.26/633.26); 3b, 1H NMR
(300 MHz, CD3OD) d 9.02 (s, 3H), 8.92 (d, J = 6.0 Hz,
3H), 8.40 (d, J = 8.4 Hz, 3H), 8.01 (dd, J = 8.1, 6.0 Hz,
3H), 7.35 (s, 3H), 4.81 (t, J = 7.2 Hz, 6H), 2.64 (t,
J = 6.9 Hz, 6H) 2.58 (s, 9H), 2.35 (m, 6H) ppm; 13C
NMR (75 MHz, CD3OD) d 147.5, 145.8, 143.4, 141.3,
134.9, 128.8, 125.3, 89.9, 81.5, 62.2, 31.0, 18.7, 17.2 ppm;
ESI-MS: m/z 711.7 [M]1+ (calcd for [C39H42N3Br2]1+
710.18/712.18/714.18),
632.0
[M]2+
(calcd
for
[C39H42N3Br]2+ 631.26/633.26); 4b, 1H NMR (300 MHz,
CD3OD) d 8.94 (s, 3H), 8.84 (d, J = 6.0 Hz, 3H), 8.42 (d,
J = 8.4 Hz, 3H), 7.98 (dd, J = 8.1, 6.0 Hz, 3H), 6.86 (s,
3H), 4.62 (t, J = 7.8 Hz, 6H), 2.59 (s, 9H), 2.57 (t,
J = 7.5 Hz, 6H) 2.06 (m, 6H), 1.69 (m, 6H), 1.43 (m, 6H)
ppm; 13C NMR (75 MHz, CD3OD) d 147.2, 145.5, 143.4,
143.0, 141.2, 128.7, 127.2, 62.9, 36.7, 32.5, 32.2, 27.0,
18.7 ppm; ESI-MS: m/z 722.1/724.1/726.1 [M]1+ (calcd for
[C39H42N3Br2]1+ 722.27/724.27/726.27).
24. Schulz, D. W.; Zigmond, R. E. Neurosci. Lett. 1989, 98,
310.
25. Grady, S.; Marks, M. J.; Wonnacott, S.; Collins, A. C.
J. Neurochem. 1992, 59, 848.